ETM1
MCID: ESS001
MIFTS: 59

Essential Tremor (ETM1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Essential Tremor

Aliases & Descriptions for Essential Tremor:

Name: Essential Tremor 54 12 50 25 51 29 52 42 14 69
Benign Essential Tremor 12 50 25
Tremor, Hereditary Essential, 1 50 69
Tremor, Hereditary Essential 1 66 29
Hereditary Essential Tremor 50 25
Familial Tremor 25 69
Etm1 50 66
Essential Tremor, Susceptibility to 13
Tremor Hereditary Essential, 1 50
Hereditary Essential Tremor 1 24
Tremor Familial Essential, 1 50
Essential Hereditary Tremor 12
Familial Essential Tremor 50
Presenile Tremor Syndrome 50
Shaky Hand Syndrome 12
Fet1 50

Characteristics:

HPO:

32
essential tremor:
Inheritance autosomal dominant inheritance
Onset and clinical course progressive


Classifications:



External Ids:

OMIM 54 190300
Disease Ontology 12 DOID:4990
ICD10 33 G25.0
MeSH 42 D020329
MedGen 40 C1860861
UMLS 69 C0270736

Summaries for Essential Tremor

NINDS : 51 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary : Essential Tremor, also known as benign essential tremor, is related to personality disorder and hereditary essential tremor 5, and has symptoms including dysarthria, postural tremor and hand tremor. An important gene associated with Essential Tremor is DRD3 (Dopamine Receptor D3), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and tongue, and related phenotypes are behavior/neurological and nervous system

Disease Ontology : 12 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference : 25 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

NIH Rare Diseases : 50 essential tremor is the most common movement disorder.  it is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. it is distinguished from tremor that results from other disorders or known causes, such as tremors seen with parkinson disease or head trauma. most cases of essential tremor are hereditary. there are five forms of essential tremor that are based on different genetic causes. several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. in mild cases, treatment may not be necessary. in cases where symptoms interfere with daily living, medications may help to relieve symptoms.      last updated: 9/12/2014

OMIM : 54 Essential tremor may be the most common human movement disorder. The main feature of essential tremor is postural... (190300) more...

UniProtKB/Swiss-Prot : 66 Tremor, hereditary essential 1: A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles also may be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.

Wikipedia : 71 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is the... more...

Related Diseases for Essential Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 2 Essential Tremor
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Hereditary Essential Tremor 5

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.2 DRD3 FMR1 SLC6A3 SNCA
2 hereditary essential tremor 5 12.0
3 sensorineural hearing loss-early graying-essential tremor syndrome 12.0
4 tremor 11.6
5 mental retardation, autosomal recessive 48 11.0
6 tremor, hereditary essential, 4 11.0
7 tremor, nystagmus, and duodenal ulcer 11.0
8 nephronophthisis-like nephropathy 1 10.8
9 dystonia 10.2
10 pyromania 10.1 DRD3 SLC6A3
11 ceroid lipofuscinosis, neuronal, 1 10.1 LRRK2 SNCA
12 lethal congenital contracture syndrome 8 10.1 LRRK2 SNCA
13 spink1-related hereditary pancreatitis 10.1 LRRK2 SNCA
14 thrombosis 10.1 LRRK2 SNCA
15 lower gum cancer 10.1 LRRK2 SLC6A3 SNCA
16 cervicitis 10.0
17 cervical dystonia 10.0
18 ovarian mucinous adenocarcinoma 10.0 SLC1A2 SLC6A3 SNCA
19 meier-gorlin syndrome 5 10.0 LRRK2 SLC6A3 SNCA
20 cardiomyopathy, dilated, 1u 10.0 FUS LRRK2 SNCA
21 trichothiodystrophy 3, photosensitive 10.0 HTRA2 LRRK2 SNCA
22 autism 19 10.0 LRRK2 SLC6A3 SNCA
23 coenzyme q10 deficiency, primary, 1 10.0 LRRK2 SLC6A3 SNCA
24 gallbladder adenoma 10.0 LRRK2 SLC6A3 SNCA
25 ataxia 10.0
26 hemochromatosis, type 2a 9.9 DRD3 LRRK2 SLC6A3 SNCA
27 riedel's fibrosing thyroiditis 9.9 LRRK2 SNCA
28 eumycotic mycetoma 9.9 FUS LRRK2 SLC6A3 SNCA
29 substance-induced psychosis 9.9 LRRK2 SLC6A3 SNCA
30 neuronitis 9.9
31 dementia 9.9
32 multiple system atrophy 9.9
33 restless legs syndrome 9.9
34 epithelioid type angiomyolipoma 9.9 LRRK2 SLC6A3 SNCA
35 transient neonatal myasthenia gravis 9.9 DNAJC13 LRRK2 SNCA
36 sarcoma 9.8
37 cerebritis 9.8
38 cavernous hemangioma 9.8 DRD3 FMR1 LRRK2 SLC6A3 SNCA
39 cerebellar degeneration 9.6
40 hypothyroidism 9.6
41 cerebellar ataxia 9.6
42 normal pressure hydrocephalus 9.6
43 autonomic dysfunction 9.6
44 alzheimer disease 9.6
45 epilepsy 9.6
46 hypotonia 9.6
47 obsessive-compulsive disorder 9.6
48 klinefelter's syndrome 9.6
49 lateral sclerosis 9.6
50 hereditary ataxia 9.6

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to Essential Tremor

Symptoms & Phenotypes for Essential Tremor

Symptoms by clinical synopsis from OMIM:

190300

Clinical features from OMIM:

190300

Human phenotypes related to Essential Tremor:

32
id Description HPO Frequency HPO Source Accession
1 dysarthria 32 HP:0001260
2 postural tremor 32 HP:0002174
3 hand tremor 32 HP:0002378

UMLS symptoms related to Essential Tremor:


essential and other specified forms of tremor, tremor, senile tremor, action tremor, physiological tremor, tremor nec in icd9cm_2014

MGI Mouse Phenotypes related to Essential Tremor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 SNCA TENM4 DRD3 FMR1 HTRA2 LRRK2
2 nervous system MP:0003631 9.23 DRD3 FMR1 HTRA2 LRRK2 SLC1A2 SLC6A3

Drugs & Therapeutics for Essential Tremor

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6 Dopamine Agents Phase 4,Phase 3
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antiparkinson Agents Phase 4,Phase 3
11 Excitatory Amino Acid Antagonists Phase 4
12 Excitatory Amino Acids Phase 4
13 Analgesics Phase 4,Phase 2,Phase 3
14 Anti-Anxiety Agents Phase 4,Phase 1
15 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
16 calcium channel blockers Phase 4,Phase 2
17 Calcium, Dietary Phase 4,Phase 2
18 Psychotropic Drugs Phase 4,Phase 1
19 Tranquilizing Agents Phase 4,Phase 1
20 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Adrenergic Antagonists Phase 4
22 Adrenergic beta-Antagonists Phase 4
23 Anti-Arrhythmia Agents Phase 4,Phase 1
24 Antihypertensive Agents Phase 4,Phase 1
25 Botulinum Toxins Phase 4,Phase 3,Phase 2
26 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Vasodilator Agents Phase 4
28 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
29 cadexomer iodine Phase 4
30
Iodine Phase 4 7553-56-2 807
31 Calamus Nutraceutical Phase 4
32
Cocaine Approved, Illicit Phase 3 50-36-2 5760 446220
33
Topiramate Approved Phase 3 97240-79-4 5284627
34
Oxymetazoline Approved Phase 3,Phase 1 1491-59-4 4636
35
Phenylephrine Approved Phase 3,Phase 1 59-42-7 6041
36 Anesthetics Phase 3,Phase 2,Phase 1
37 Anesthetics, Local Phase 3
38 Dopamine Uptake Inhibitors Phase 3
39 Neurotransmitter Uptake Inhibitors Phase 3
40 Vasoconstrictor Agents Phase 3
41 Anti-Obesity Agents Phase 3
42 Neuroprotective Agents Phase 3,Phase 1,Phase 2
43 Protective Agents Phase 3,Phase 2,Phase 1
44 Adrenergic Agonists Phase 3,Phase 2,Phase 1
45 Adrenergic beta-2 Receptor Agonists Phase 3,Phase 2,Phase 1
46 Adrenergic beta-Agonists Phase 3,Phase 2,Phase 1
47 Anti-Asthmatic Agents Phase 3,Phase 2,Phase 1
48 Autonomic Agents Phase 3,Phase 2,Phase 1
49 Bromides Phase 3,Phase 2,Phase 1
50 Bronchodilator Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 204)
id Name Status NCT ID Phase
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
2 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4
3 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4
4 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4
5 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4
6 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
7 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
8 Atlas Predicted DBS Settings in Essential Tremor Enrolling by invitation NCT02678429 Phase 4
9 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4
10 Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor Unknown status NCT00724906 Phase 3
11 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3
12 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause. Completed NCT00236496 Phase 3
13 Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3
14 Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS Completed NCT02549859 Phase 2, Phase 3
15 Tiotropium and Salmeterol PK Study in COPD Patients Completed NCT00673478 Phase 3
16 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Recruiting NCT02555982 Phase 3
17 Pre-lemniscal Radiation Deep Brain Stimulation for ET Terminated NCT00634478 Phase 2, Phase 3
18 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor Withdrawn NCT01441284 Phase 3
19 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3
20 A Safety/Efficacy Trial of Zonisamide for Essential Tremor Completed NCT00223743 Phase 2
21 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor Completed NCT00598078 Phase 2
22 A Pilot Efficacy and Safety Study of ST101 in Essential Tremor Completed NCT01332695 Phase 2
23 A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2
24 Octanol to Treat Essential Tremor Completed NCT00080366 Phase 2
25 Efficacy of Levetiracetam in Essential Tremor Completed NCT00620165 Phase 1, Phase 2
26 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2
27 Evaluate SAGE-547 in Patients With Essential Tremor Completed NCT02277106 Phase 2
28 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2
29 Botulinum Toxin A to Treat Arm Tremor Completed NCT02207946 Phase 2
30 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2
31 Effect of Alcohol on Tremors Completed NCT00001925 Phase 2
32 Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02242266 Phase 2
33 Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02242227 Phase 2
34 Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02238106 Phase 2
35 Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment Recruiting NCT02551848 Phase 2
36 A Study to Evaluate SAGE-217 in Subjects With Essential Tremor Recruiting NCT02978781 Phase 2
37 Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres? Recruiting NCT02960243 Phase 1, Phase 2
38 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Recruiting NCT01945567 Phase 2
39 Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study Recruiting NCT02585583 Phase 2
40 An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor Active, not recruiting NCT02668146 Phase 2
41 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Enrolling by invitation NCT02427646 Phase 2
42 A Phase 2 RCT Study of CX-8998 for Essential Tremor Not yet recruiting NCT03101241 Phase 2
43 A Study of T2000 in Essential Tremor Terminated NCT00321087 Phase 2
44 T2000 in Essential Tremor - Open Label Continuation Terminated NCT00655278 Phase 2
45 Octanoic Acid for Essential Tremor Completed NCT01468948 Phase 1
46 1-Octanol to Treat Essential Tremor Completed NCT00016679 Phase 1
47 1-Octanol to Treat Essential Tremor Completed NCT00001986 Phase 1
48 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT02037217 Phase 1
49 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT01304758 Phase 1
50 Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders Completed NCT01698450 Phase 1

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

Genetic tests related to Essential Tremor:

id Genetic test Affiliating Genes
1 Hereditary Essential Tremor 1 29 24 DRD3
2 Essential Tremor 29

Anatomical Context for Essential Tremor

MalaCards organs/tissues related to Essential Tremor:

39
Brain, Cerebellum, Tongue, Cortex, Testes, Thalamus, Subthalamic Nucleus

Publications for Essential Tremor

Articles related to Essential Tremor:

(show top 50) (show all 697)
id Title Authors Year
1
Coronal Transcranial Sonography and M-Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. ( 28426143 )
2017
2
A data mining approach using cortical thickness for diagnosis and characterization of essential tremor. ( 28526878 )
2017
3
Early Head Tremor in Essential Tremor: A Case Series and Commentary. ( 28373926 )
2017
4
A computerized tablet system for evaluating treatment of essential tremor by magnetic resonance guided focused ultrasound. ( 28412948 )
2017
5
A Network Model of Local Field Potential Activity in Essential Tremor and the Impact of Deep Brain Stimulation. ( 28068428 )
2017
6
Efficacy of Fiber Tractography in the Stereotactic Surgery of the Thalamus for Patients with Essential Tremor. ( 28458383 )
2017
7
Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. ( 28409750 )
2017
8
Letter: Thalamotomy-Like Effects From Partial Removal of a Ventral Intermediate Nucleus Deep Brain Stimulator Lead in a Patient With Essential Tremor: Case Report. ( 28379503 )
2017
9
Thalamic DBS with a constant-current device in essential tremor: AA controlled clinical trial. ( 28400200 )
2017
10
Equivalence of cell survival data for radiation dose and thermal dose in ablative treatments: analysis applied to essential tremor thalamotomy by focused ultrasound and gamma knife. ( 28044461 )
2017
11
Emotion modulation of the startle reflex in essential tremor: Blunted reactivity to unpleasant and pleasant pictures. ( 27887893 )
2017
12
Probabilistic mapping of deep brain stimulation effects in essential tremor. ( 27981031 )
2017
13
Topography of essential tremor. ( 28442304 )
2017
14
Emerging strategies in the management of essential tremor. ( 28382111 )
2017
15
Awareness of cognitive impairment in individuals with essential tremor. ( 28477687 )
2017
16
Topiramate for essential tremor. ( 28409827 )
2017
17
Mutation analysis of CHCHD2 gene in Chinese Han familial essential tremor patients and familial Parkinson's disease patients. ( 27814991 )
2017
18
Support System to Improve Reading Activity in Parkinson's Disease and Essential Tremor Patients. ( 28467366 )
2017
19
Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. ( 28503363 )
2017
20
Feasibility study: Effect of hand resistance exercise on handwriting in Parkinson's disease and essential tremor. ( 28389133 )
2017
21
Non-invasive Brain Stimulation for Essential Tremor. ( 28373927 )
2017
22
Action Tremor Asymmetry Profile Does Not Aggregate in Families with Essential Tremor. ( 28469594 )
2017
23
Role of altered cerebello-thalamo-cortical network in the neurobiology of essential tremor. ( 28062908 )
2017
24
Cognitive Dysfunction Is Associated with Greater Imbalance and Falls in Essential Tremor. ( 28469597 )
2017
25
Obsessive compulsive personality disorder in Progressive Supranuclear Palsy, Multiple System Atrophy and Essential Tremor. ( 27364040 )
2016
26
Cerebellar dysfunction in essential tremor. ( 27062434 )
2016
27
SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. ( 27206883 )
2016
28
Patients with essential tremor can have manual dexterity and attention deficits with no impairments in other cognitive functions. ( 26982989 )
2016
29
A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. ( 27456607 )
2016
30
Movement disorders: Novel genetic risk variants for essential tremor. ( 27811916 )
2016
31
Deep Brain Stimulation Salvages a Flourishing Dental Practice: A Dentist with Essential Tremor Recounts his Experience. ( 27909628 )
2016
32
Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study. ( 27624392 )
2016
33
Precise stimulation location optimizes speech outcomes in essential tremor. ( 27595548 )
2016
34
Nonlinear interactions in the thalamocortical loop in essential tremor: A model-based frequency domain analysis. ( 26987955 )
2016
35
Genome-wide association study in essential tremor identifies three new loci. ( 27797806 )
2016
36
A Trial of Focused Ultrasound Thalamotomy for Essential Tremor. ( 27959759 )
2016
37
Development of method for quantifying essential tremor using a small optical device. ( 27058772 )
2016
38
Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future. ( 27101283 )
2016
39
A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. ( 27557301 )
2016
40
Treatment of Medically Refractory Essential Tremor. ( 27557307 )
2016
41
Agnosia for head tremor in essential tremor: prevalence and clinical correlates. ( 26877883 )
2016
42
Cerebellar involvement in essential tremor with and without resting tremor: A Diffusion Tensor Imaging study. ( 27050442 )
2016
43
A suggested minimum standard deep brain stimulation evaluation for essential tremor. ( 26944141 )
2016
44
Time reproduction deficits in essential tremor patients. ( 27091412 )
2016
45
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. ( 27545646 )
2016
46
Taking on Essential Tremor: New Tools and Approaches Offer patients Increased Treatment Options. ( 27187536 )
2016
47
Current concepts of essential tremor. ( 27561441 )
2016
48
Clinical validation of a precision electromagnetic tremor measurement system in participants receiving deep brain stimulation for essential tremor. ( 27511464 )
2016
49
Immediate and Longitudinal Alterations of Functional Networks after Thalamotomy in Essential Tremor. ( 27822200 )
2016
50
More Time with Tremor: The Experience of Essential Tremor Versus Parkinson's Disease Patients. ( 27430000 )
2016

Variations for Essential Tremor

Expression for Essential Tremor

Search GEO for disease gene expression data for Essential Tremor.

Pathways for Essential Tremor

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.77 FMR1 LRRK2 SLC1A2 SNCA
2 10.85 HTRA2 LRRK2 SLC6A3 SNCA
3 10.66 SLC6A3 SNCA

GO Terms for Essential Tremor

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.62 FUS LRRK2 SLC6A3 SNCA
2 growth cone GO:0030426 9.54 FMR1 LRRK2 SNCA
3 polysome GO:0005844 9.48 FMR1 FUS
4 neuron projection GO:0043005 9.46 FMR1 LRRK2 SLC6A3 TENM4
5 perikaryon GO:0043204 9.43 FMR1 FUS LRRK2
6 inclusion body GO:0016234 9.4 LRRK2 SNCA
7 postsynapse GO:0098794 9.13 FMR1 LRRK2 SNCA
8 axon GO:0030424 9.02 FMR1 LRRK2 SLC1A2 SLC6A3 SNCA
9 membrane GO:0016020 10.2 ANO3 DNAJC13 DRD3 FMR1 HTRA2 LINGO2
10 plasma membrane GO:0005886 10.09 ANO3 DNAJC13 DRD3 FMR1 LRRK2 SLC1A2

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.74 HTRA2 SLC6A3 SNCA
2 response to drug GO:0042493 9.73 DRD3 SLC1A2 SLC6A3 SNCA
3 cellular response to oxidative stress GO:0034599 9.58 HTRA2 LRRK2 SNCA
4 regulation of multicellular organism growth GO:0040014 9.56 DRD3 HTRA2
5 regulation of dopamine secretion GO:0014059 9.55 DRD3 SNCA
6 behavioral response to cocaine GO:0048148 9.54 DRD3 SNCA
7 regulation of neuron death GO:1901214 9.52 LRRK2 SNCA
8 synaptic transmission, dopaminergic GO:0001963 9.51 DRD3 SNCA
9 regulation of neurotransmitter secretion GO:0046928 9.49 FMR1 SNCA
10 dopamine metabolic process GO:0042417 9.48 DRD3 SNCA
11 prepulse inhibition GO:0060134 9.46 DRD3 SLC6A3
12 negative regulation of neuron death GO:1901215 9.43 HTRA2 LRRK2 SNCA
13 dopamine biosynthetic process GO:0042416 9.37 SLC6A3 SNCA
14 dopamine uptake involved in synaptic transmission GO:0051583 9.32 SLC6A3 SNCA
15 positive regulation of dopamine receptor signaling pathway GO:0060161 9.16 DRD3 LRRK2
16 response to cocaine GO:0042220 9.13 DRD3 SLC6A3 SNCA
17 regulation of locomotion GO:0040012 8.8 DRD3 LRRK2 SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.43 FMR1 LRRK2 SNCA
2 identical protein binding GO:0042802 9.35 FMR1 FUS HTRA2 LRRK2 SNCA
3 dynein complex binding GO:0070840 9.16 FMR1 SNCA
4 dopamine binding GO:0035240 8.62 DRD3 SLC6A3

Sources for Essential Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....